$1,318.00
This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed and pipeline drugs, clinical trials, patent information, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed drugs, clinical trials, probability of success, patent information, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Prophylaxis and monitoring
8 Volume expansion
8 Medical therapies
8 Renal replacement therapy
10 EPIDEMIOLOGY
10 Incidence assumptions
19 MARKETED DRUGS
21 PROBABILITY OF SUCCESS
22 REVENUE OPPORTUNITY
23 CLINICAL TRIAL LANDSCAPE
24 Sponsors by status
25 Sponsors by phase
26 BIBLIOGRAPHY
26 Prescription information
27 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in incident cases of TLS in selected high-risk malignancies, 2017–26
21 Figure 2: Probability of success in the TLS pipeline
23 Figure 3: Clinical trials in TLS
23 Figure 4: Top 10 drugs for clinical trials in TLS
24 Figure 5: Top 10 companies for clinical trials in TLS
24 Figure 6: Trial locations in TLS
25 Figure 7: TLS trials status
25 Figure 8: TLS trials sponsors, by phase
LIST OF TABLES
11 Table 1: Incident cases of TLS in selected high-risk malignancies, 2017–26
13 Table 2: Incidence of acute myeloid leukemia, and proportion of individuals with TLS, 2017
14 Table 3: Incident cases of TLS in acute myeloid leukemia, 2017–26
15 Table 4: Incidence of acute lymphocytic leukemia, and proportion of individuals with TLS, 2017
16 Table 5: Incident cases of TLS in acute lymphocytic leukemia, 2017–26
17 Table 6: Incidence of Burkitt’s lymphoma, and proportion of individuals with TLS, 2017
18 Table 7: Incident cases of TLS in Burkitt’s lymphoma, 2017–26
20 Table 8: Marketed drugs for TLS
22 Table 9: Historical global sales, by drug ($m), 2015–19
22 Table 10: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!